Authors
Ziyu Tang, Jinze Li, Shixiang Qiu, Yunguo Liao, Hong Hu, Bolin Gou, Jiaqi Pu, Xin Wei, Chao Li
Published in
Brachytherapy. Aug 18, 2026. Epub Aug 18, 2026.
Abstract
To evaluate the efficacy and safety of CT-guided iodine-125 (¹²⁵I) radioactive seed implantation in non-small cell lung cancer (NSCLC) patients with severe pulmonary dysfunction.
A retrospective analysis was performed on 56 NSCLC patients with severe pulmonary dysfunction who underwent ¹²⁵I seed implantation at Nanchong Central Hospital from January 2020 to December 2024. Short-term efficacy, survival outcomes, pulmonary function, Karnofsky Performance Status (KPS), and adverse events were observed. Prognostic factors were analyzed by Cox regression.
The 1-year objective response rate (ORR) was 60.7% and disease control rate (DCR) was 67.9%. The median overall survival (OS) was 18.0 months, and median progression-free survival (PFS) was 13.0 months. Multivariate analysis showed that tumor maximum diameter, D90 ≥120 Gy, and postoperative systemic therapy were independent prognostic factors for OS and PFS. The most common adverse event was pneumothorax requiring drainage (25.0%), with no grade ≥3 radiation pneumonitis or treatment-related deaths. Pulmonary function and KPS scores showed no significant deterioration within 12 months postoperatively.
CT-guided ¹²⁵I seed implantation is effective and safe for NSCLC patients with severe pulmonary dysfunction, with favorable tumor control and survival while preserving pulmonary function without significant decline within 12 months.
PMID:
42613271
Bibliographic data and abstract were imported from PubMed on 19 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0